INNOGEN-B

Guangzhou Innogen Pharmaceutical Group-B (2591.HK) fell approximately 21% today, primarily driven by profit-taking ahead of the Q2 earnings season and pressures from a diverging GLP-1 sector. The stock opened at HK$4.36, touched a morning high of HK$4.42, but reversed sharply in the afternoon to hit an intraday low of HK$4.20, closing at HK$4.28, up 0.94% from the previous close of HK$4.24. Volume reached 9.402 million shares with a turnover rate of 2.24%. For Q4 2025, revenue was HK$41.74 million, but net loss widened to HK$121.7 million, a 130.15% YoY increase, with EPS of -HK$0.2717; PB stood at 1.68x, while PE remained negative. Despite recent positive catalysts such as PIC/S GMP certification and NMPA approval for an adolescent obesity trial, the market awaits the upcoming board meeting on August 31 for interim results and dividend decisions.

银诺医药-B（2591.HK）今日上午盘低开低走，大幅下挫，截至 9:38 报 4.255 港元，较前收 4.490 港元跌约 5.23%，且一度触及 4.250 港元逼近 52 周低点，成交量约 109 万股，换手率 0.26%。暴跌主因是港股开盘后市场情绪极不稳定，该股早盘即出现剧烈波动，盘中跌幅一度超 21%，相关报道指出其香港开盘表现异常。公司前收 4.490 港元已较 52 周高位 74 港元跌去 94.25%，YTD 跌幅达 86.01%，且当前股价远低于 MA20（6.889 港元）和 MA60（8.067 港元），技术面持续承压。基本面方面，公司仍处亏损状态，Q4 2025 净亏损约 1.22 亿港元，同比扩大 130.15%，营收约 4174 万港元，净利率为-291.6%，盈利前景尚不明朗。不过，公司近期获得 PIC/S GMP 认证，依苏帕格鲁肽α全球商业化进程或有加速可能。

Innogen Pharmaceutical-B (2591.HK) plunged 5.1% to close at 4.54 HKD in the morning session, with an intraday drop of up to 21%, as profit-taking ensued after the previous rally and market sentiment weakened. The company had just received PIC/S GMP certificates from ANVISA to accelerate the global expansion of efsubaglutide alfa (Yinuoqing) and won NMPA approval for an adolescent obesity trial recently. However, the stock has collapsed 93.86% from its 52-week high of 74 HKD, with a YTD decline of 85.08%, and the current price has fallen below both the MA20 (7.096 HKD) and MA60 (8.199 HKD). For Q4 2025, net loss widened to 122 million HKD, with EPS at -0.27 HKD, deteriorating 115.95% YoY, underscoring fundamental weakness. The broader HSI rebounded over 400 points today, led by chip and shipping stocks, which may offer some support.

Guangzhou Innogen Pharmaceutical opened at the day's high of 6.630 and immediately fell to 6.215, closing down 5.98% from the previous close of 6.610, hitting an all-time low on just 45,800 shares traded in the morning session. The company announced a board meeting on August 27 to review interim results, while the market priced in worsening losses; Q4 2025 net loss widened to HKD 121.7 million, up 130% YoY, with EPS of -HKD 0.272. The stock is now 91.6% below its 52-week high of HKD 74 and has dropped 79.57% YTD, trading well below MA20 (7.366) and MA60 (8.349), signaling persistent technical weakness. However, recent ANVISA PIC/S GMP certification for two contract sites and NMPA approval for adolescent obesity trials could support the long-term pipeline.

Innogen Pharmaceutical (2591.HK) staged a single-sided decline during the morning session on the Hong Kong Stock Exchange, slumping to a new 52-week low of HKD 6.705 before closing at HKD 6.735, down 4.8% from the prior close of HKD 7.075. Despite yesterday's announcement of a board meeting to review interim results and dividends, the lack of fresh positive catalysts left the stock vulnerable to fundamental headwinds: Q4 2025 EPS widened to -HKD 0.2717, net profit plunged 130.15% YoY, and net profit margin remained deeply negative at -291.6%. Year-to-date, the stock has lost 77.86% and trades well below its MA20 (HKD 7.469) and MA60 (HKD 8.474), underscoring a persistent downtrend. However, the recent receipt of PIC/S GMP certification for global expansion may offer a counterbalance going forward.